7 unknown, 5 completed, 3 active not recruiting, 3 terminated. 9 Phase 2, 6 Not applicable, 4 Phase 3, 3 Phase 1, 1 Early Phase 1.
Follow GEM: new trials by email Literature Review of GEM trials Research Report on GEM
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma Glofitamab, Gemcitabin, Oxaliplatin - Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2026-01-01 | 2026-03-18 |
| Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response PD-1 blocking antibody, Gemcitabine, Cisplatin (80 mg/m2) - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Sun Yat-sen University | 593 | 2024-03-01 | 2026-03-06 |
| Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE) Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 3 | Active not recruiting | Sun Yat-sen University | 490 | 2023-08-01 | 2025-01-23 |
| Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma Nimotuzumab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma by AJCC V8 Stage | Not applicable | Recruiting | Fourth Affiliated Hospital of Guangxi Medical University | 288 | 2022-12-01 | 2023-02-08 |
| CGM Plus GEM in Prediabetes GEM, Routine Care - PreDiabetes | Not applicable | Completed | University of Colorado, Denver | 61 | 2022-11-01 | 2026-06-03 |
| Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma Camrelizumab, Gemcitabine, Induction Cisplatin - Nasopharyngeal Carcinoma | Phase 2 | Unknown | Wei Jiang | 200 | 2022-04-06 | 2023-03-23 |
| Investigator-initiated Clinical Trial of MIKE-1 Am80, Gemcitabine, nab-Paclitaxel - Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | Nagoya University | 55 | 2021-08-23 | 2024-04-04 |
| PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2) - Nasopharyngeal Carcinoma | Phase 3 | Active not recruiting | Sun Yat-sen University | 532 | 2021-08-01 | 2025-07-16 |
| Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma PD-1 blocking antibody, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 152 | 2020-03-16 | 2025-07-17 |
| Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma Toripalimab, Gemcitabine, 5- fluorine pyrimidine - Advanced Cholangiocarcinoma | Phase 2 | Unknown | Jiangmen Central Hospital | 30 | 2019-07-13 | 2019-07-16 |
| The GEM (Goals for Eating and Moving) Study GEM, Enhanced Usual Care - Weight Gain, Obesity | Not applicable | Completed | NYU Langone Health | 489 | 2017-11-20 | 2023-04-27 |
| Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma PEGPH20, CIS, GEM - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic | Phase 1 | Terminated | Halozyme Therapeutics | 85 | 2017-10-02 | 2020-02-07 |
| Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer CD8+NKG2D+ AKT Cell, Gemcitabine - Pancreatic Ductal Adenocarcinoma | Early Phase 1 | Unknown | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 72 | 2016-08-01 | 2016-10-11 |
| Energy Balance Following Islet Transplantation Accelerometer, Anthropomentry, Blood tests - Type 1 Diabetes | Not applicable | Terminated | University of Edinburgh | 2 | 2016-06-01 | 2019-10-25 |
| PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer NVB, EPI, DDP - Breast Cancer Model, Effects of Chemotherapy | Phase 3 | Unknown | Shi Yanxia | 320 | 2016-04-01 | 2017-01-16 |
| Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer EndostarTM Injection, Gemcitabine, Navelbine - Breast Neoplasms | Phase 2 | Unknown | Xinjiang Medical University | 120 | 2015-10-01 | 2017-07-17 |
| Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1) Gemcitabine, SBRT - Pancreatic Cancer | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 513 | 2015-08-01 | 2017-04-05 |
| DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise Exercise - DNA Methylation | Not applicable | Completed | University of Colorado, Boulder | 276 | 2014-01-01 | 2023-08-01 |
| Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations GEM - Diabetes Mellitus, Type 2 | Not applicable | Completed | University of Virginia | 47 | 2013-05-01 | 2015-05-04 |
Showing 20 of 21. Sign in to see all of them.
Nasopharyngeal Carcinoma (6) · Pancreatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma (1) · Carcinoma in Situ (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Lymphoma, Large B-Cell, Diffuse (1) · Motor Activity (1) · Nasopharyngeal Neoplasms (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Obesity (1)
Sun Yat-sen University (4) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Fourth Affiliated Hospital of Guangxi Medical University (1) · Halozyme Therapeutics (1) · Jiangmen Central Hospital (1) · NYU Langone Health (1) · Nagoya University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shi Yanxia (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · University of Colorado, Boulder (1) · University of Colorado, Denver (1) · University of Edinburgh (1)
China (13) · United States (6) · Japan (1) · South Korea (1) · Thailand (1) · United Kingdom (1)
Jun Ma, M.D. (3) · Ana De Jesus-Acosta, MD (1) · Angela Bryan, PhD (1) · Bin Zhang, M.D. (1) · Cao Xinxin (1) · Daniel Cox, PhD (1) · Hiroki Kawashima (1) · Jian Zhang, M.D. (1) · Jun Ma (1) · Melanie Jay, MD (1) · Mitsuhiro Fujishiro (1) · Shareen Forbes, MD (1) · Shun-E Yang, Professor (1) · Tamara Oser, MD (1)
PMID 28837405, PMID 29584545, PMID 30213452, PMID 31150573, PMID 33492986, PMID 19171491, PMID 23510863, PMID 30565055, PMID 30766686, PMID 31229622, PMID 32969699, PMID 33633498, PMID 34051177, PMID 34856961, PMID 34990291, PMID 35240053, PMID 35355438, PMID 35941566, PMID 35986837, PMID 35997729, PMID 36746459, PMID 37596191, PMID 37801967, PMID 38265030, PMID 38740030, PMID 39313341, PMID 40839372, PMID 41690301
R01CA179963 (1)